Gyre Therapeutics, Inc. - Common Stock GYRE 深 滬
等待開盤 09-17 09:30:00 美东时间
7.59
-0.310
-3.92%
華盛通- 最 高7.94
- 今 開7.88
- 成交量 5.50万股
- 最 低 7.55
- 昨 收 7.90
- 總市值 7.31亿
- 52周最高 19.00
- 市盈率 靜 157.80
- 換手率 0.06%
- 52周最低 6.11
- 委 比 48.72%
- 總股本 9631.32万
- 歷史最高 29271.2116
- 量 比 0.54
- 振 幅 4.94%
- 歷史最低 -19.80
- 每 手 1
- 風險率 2.39%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Gyre Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Gyre Therapeutics announced that its management will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025, at 12:30 p.m. ET. The live webcast and replay will be available on Gyre’s website. Gyre focuses on developing therapies for fibrosis, particularly Hydronidone for liver fibrosis, and is expanding its pipeline in China through Gyre Pharmaceuticals.
09-05 20:05
Gyre Therapeutics Appoints Dan Weng to Board
Gyre Therapeutics ( ($GYRE) ) has shared an update. On August 18, 2025, Gyre Th...
08-22 19:28
Gyre Therapeutics Announces the Appointment of Dan Weng, M.D., to Board of Directors
Gyre Therapeutics appoints Dan Weng, M.D., to its Board of Directors. Dr. Weng brings nearly four decades of experience in global clinical trials and holds leadership roles in several prominent CROs. Gyre, a biopharmaceutical company, focuses on developing therapies for organ fibrosis. Its flagship product, ETUARY® (Pirfenidone capsule), is a leading treatment for IPF in China. The company is also advancing Hydronidone and other therapies for var...
08-22 11:00
Gyre Therapeutics Appoints Ping Zhang as Interim CEO
Gyre Therapeutics ( ($GYRE) ) just unveiled an update. On August 5, 2025, Gyre ...
08-12 04:45
Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China
Gyre Therapeutics has initiated a Phase 1 clinical trial for its novel ETA receptor antagonist, F230, targeting pulmonary arterial hypertension (PAH). This marks Gyre's entry into the PAH field, a rare and severe cardiovascular condition with limited treatment options. F230, licensed from Eisai Co., Ltd., is designed to selectively block the ETA receptor to reduce pulmonary vascular remodeling and lower pulmonary pressure. The trial aims to asses...
06-10 11:00
Gyre Therapeutics Announces Closing of its Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Gyre Therapeutics closed an underwritten public offering of 2,555,555 shares of common stock, including an additional 333,333 shares, at $9.00 per share, raising approximately $23.0 million in gross proceeds. The company plans to use the net proceeds to advance its Phase 2 clinical trial for F351 in metabolic dysfunction-associated steatohepatitis (MASH)-related liver fibrosis, as well as for research and development, manufacturing, and general c...
05-29 20:01
MAC Copper, ATS, Pony AI And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were higher, with the Dow Jones index gaining around 500 points on ...
05-27 22:56
Gyre Therapeutics slumps 16%, prices $20M stock offering
Gyre Therapeutics (NASDAQ:GYRE) priced its previously announced underwritten public offering of ~2.22M shares at a public offering price of $9.00 per share. Underwriters have a 30 option to purchase...
05-23 15:35
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Tiziana Life Sciences (NASDAQ:TLSA) shares increased by 10.2% to $1.51...
05-23 05:05
Gyre Therapeutics shares are trading lower after the company announced a proposal for a public offering.
Gyre Therapeutics shares are trading lower after the company announced a propos...
05-23 04:38
